Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L [Thoracic Oncology]
Conclusion The study did not demonstrate noninferiority of gefitinib compared with erlotinib in terms of PFS in patients with lung adenocarcinoma according to the predefined criteria. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Urata, Katakami, Morita, Kaji, Yoshioka, Seto, Satouchi, Iwamoto, Kanehara, Fujimoto, Ikeda, Murakami, Daga, Oguri, Goto, Imamura, Sugawara, Saka, Nogami, Negoro, Nakagawa, Nakanishi Tags: Chemotherapy Thoracic Oncology Source Type: research

Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study [Rapid Communication]
Purpose The development of endocrinopathies in survivors of childhood cancer as they age remains understudied. We characterized endocrine outcomes in aging survivors from the Childhood Cancer Survivor Study on the basis of therapeutic exposures. Patients and Methods We analyzed self-reported conditions in 14,290 5-year survivors from the Childhood Cancer Survivor Study, with a median age 6 years (range,
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Mostoufi-Moab, Seidel, Leisenring, Armstrong, Oeffinger, Stovall, Meacham, Green, Weathers, Ginsberg, Robison, Sklar Tags: Long Term Survival & Late Effects, Rapid Communications, Rapid Communications Source Type: research

Estimating the Influence of Obesity on Cancer Risk: Stratification by Smoking Is Critical [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Song, Giovannucci Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.) COMMENTS AND CONTROVERSIES Source Type: research

Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Molina, Hu, Nanus Tags: Surgery, Combined Modality EDITORIALS Source Type: research

Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Kao, Boyer Tags: Translational Oncology EDITORIALS Source Type: research

When Do Late Effects in Childhood Cancer Survivors Cease Emerging? The Endocrine Answer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Greenberg Tags: Long Term Survival & Late Effects EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to L.J. Eapen et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Sonpavde Tags: CORRESPONDENCE Source Type: research

Management Considerations After Cystectomy for Bladder Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Eapen, MacRae Tags: CORRESPONDENCE Source Type: research

Reply to R. Colomer et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Durkee, Qian, Goldhaber-Fiebert, Horst Tags: CORRESPONDENCE Source Type: research

Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Colomer, Pascual, Albanell Tags: CORRESPONDENCE Source Type: research

Reply to E.M. Ruggeri et al and Y.-W. Hu [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Galsky, Moshier, Wisnivesky, Mazumdar Tags: CORRESPONDENCE Source Type: research

Real-World Role of Adjuvant Chemotherapy in Bladder Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Hu Tags: CORRESPONDENCE Source Type: research

Should We Use Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer After Radical Cystectomy? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Ruggeri, Fabbri, Nelli Tags: CORRESPONDENCE Source Type: research

Oncologists Guilt [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Caram Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Innovations in American Society of Clinical Oncology Practice Guideline Development [ASCO SPECIAL ARTICLE]
Since the beginning of its guidelines program in 1993, ASCO has continually sought ways to produce a greater number of guidelines while maintaining its commitment to using the rigorous development methods that minimize the biases that threaten the validity of practice recommendations. ASCO is implementing a range of guideline development and implementation innovations. In this article, we describe innovations that are designed to (1) integrate consideration of multiple chronic conditions into practice guidelines; (2) keep more of its guidelines current by applying evolving signals or (more) rapid, for-cause updating approa...
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Somerfield, Bohlke, Browman, Denduluri, Einhaus, Hayes, Khorana, Miller, Mohile, Oliver, Ortiz, Lyman Tags: ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis [REVIEW ARTICLE]
Purpose Programmed cell death protein-1- checkpoint blockers have recently been approved as second-line treatment for advanced non–small-cell lung cancer (NSCLC). Unfortunately, only a subgroup of patients responds and shows long-term survival to these therapies. Tumor vaccines and cellular immunotherapies could synergize with checkpoint blockade, but which of these treatments is most efficacious is unknown. In this meta-analysis, we assessed the efficacy of tumor vaccination and cellular immunotherapy in NSCLC. Methods We searched for randomized controlled trials (RCTs) investigating cellular immunotherapy or vacci...
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Dammeijer, Lievense, Veerman, Hoogsteden, Hegmans, Arends, Aerts Tags: Chemotherapy, Combined Modality REVIEW ARTICLE Source Type: research

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study [Pediatric Oncology]
Purpose Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series. Materials and Met...
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Chagtai, Zill, Dainese, Wegert, Savola, Popov, Mifsud, Vujanić, Sebire, Le Bouc, Ambros, Kager, O'Sullivan, Blaise, Bergeron, Mengelbier, Gisselsson, Kool, Tytgat, van den Heuvel-Eibrink, Graf, van Tinteren, Coulomb, Gessler, Williams, Pritchard-Jo Tags: Translational Oncology, Renal Tumors, Wilms' Tumor: Therapy, Genitourinary, Cancer Biomarkers, Pediatric, Chromosomal Abnormalities Pediatric Oncology Source Type: research

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Childrens Oncology Group [Pediatric Oncology]
Purpose The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity. Methods Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed. Results Eight-year EFS was 86% (95% CI, 84% to 88%) for ...
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Gratias, Dome, Jennings, Chi, Tian, Anderson, Grundy, Mullen, Geller, Fernandez, Perlman Tags: Renal Tumors, Wilms' Tumor: Therapy Pediatric Oncology Source Type: research

How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors [Pediatric Oncology]
Conclusion The benefits of preserving vision must be balanced with the impact of eye-preserving treatments on long-term survival in heritable retinoblastoma, and the genetic background of the patient influences choice of eye-preserving treatment. Germline RB1 genetic analysis is important to identify heritable retinoblastoma among unilateral retinoblastoma cases. Eye-preserving radiotherapy should be carefully considered in patients with germline RB1 mutations. Life-long oncologic follow-up is crucial for all retinoblastoma survivors, and less detrimental eye-preserving therapies must be developed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Temming, Arendt, Viehmann, Eisele, Le Guin, Schundeln, Biewald, Mausert, Wieland, Bornfeld, Sauerwein, Eggert, Lohmann, Jockel Tags: Genetic epidemiology, Population and observational studies (SEER, WHI observational, etc.), Radiation, Chemotherapy, Retinoblastoma, Epidemiology, Osteosarcoma, Retinoblastoma, Rhabdomyosarcoma & Soft Tissue Sarcoma, Long Term Survival & Late Effects, Rad Source Type: research

Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study [Thoracic Oncology]
Conclusion Lobectomy showed better survival than sublobar resection for patients with NSCLC ≤ 1 cm and> 1 to 2 cm. For patients in whom lobectomy is unsuitable, segmentectomy should be recommended for NSCLC> 1 to 2 cm, whereas surgeons could rely on surgical skills and the patient profile to decide between segmentectomy and wedge resection for NSCLC ≤ 1 cm. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Dai, Shen, Ren, Zhong, Zheng, He, Xie, Fei, Liang, Jiang, Yang, Petersen, Ng, Liu, Rocco, Brunelli, Shen, Chen, He Tags: Surgical Oncology, Surgery Thoracic Oncology Source Type: research

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma [Sarcomas]
Conclusion Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Gounder, Zer, Tap, Salah, Dickson, Gupta, Keohan, Loong, DAngelo, Baker, Condy, Nyquist-Schultz, Tanner, Erinjeri, Jasmine, Friedlander, Carlson, Unger, Saint-Martin, Rashal, Ellis, Kauffman, Shacham, Schwartz, Abdul Razak Tags: Phase I and Clinical Pharmacology, Osteosarcoma & Ewing Sarcomas:, Rhabdo & Other Soft Tissue Sarcomas: Source Type: research

Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis [Breast Cancer]
Conclusion Our findings in a largely unadjusted analysis suggest that overweight and obesity are risk factors for cardiotoxicity from anthracyclines and sequential anthracyclines and trastuzumab. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Guenancia, Lefebvre, Cardinale, Yu, Ladoire, Ghiringhelli, Zeller, Rochette, Cottin, Vergely Tags: Chemotherapy Breast Cancer Source Type: research

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP [Hematologic Malignancy]
Conclusion The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Close to 90% of patients with DLBCL belong to the low- and intermediate-risk groups and have a CNS relapse risk 10% risk of CNS relapse and should be considered for CNS-directed investigations and prophylactic interventions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Schmitz, Zeynalova, Nickelsen, Kansara, Villa, Sehn, Glass, Scott, Gascoyne, Connors, Ziepert, Pfreundschuh, Loeffler, Savage Tags: Prognostic Studies, Chemotherapy Hematologic Malignancy Source Type: research

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis [Hematologic Malignancy]
Purpose Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD). We compared outcomes after Haplo-HCT using PT-Cy with MSD-HCT in patients with lymphoma, using the Center for International Blood and Marrow Transplant Research registry. Materials and Methods We evaluated 987 adult patients undergoing either Haplo-HCT (n = 180) or MSD-HCT (n = 807) following reduced-intensity conditioning regimens. The haploidentical group received graft-versus-host disease (GVHD) prophylaxis with...
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Ghosh, Karmali, Rocha, Ahn, DiGilio, Hari, Bachanova, Bacher, Dahi, de Lima, DSouza, Fenske, Ganguly, Kharfan-Dabaja, Prestidge, Savani, Smith, Sureda, Waller, Jaglowski, Herrera, Armand, Salit, Wagner-Johnston, Fuchs, Bolanos-Meade, Hamadani Tags: Lymphoma Hematologic Malignancy Source Type: research

Trends in Obesity Prevalence in Adults With a History of Cancer: Results From the US National Health Interview Survey, 1997 to 2014 [Epidemiology]
We examined the trend in obesity prevalence among cancer survivors in the United States in the past two decades and compared trends with those of adults without a history of cancer. Patients and Methods This was a population-based nationally representative sample of 538,969 noninstitutionalized US adults 18 to 85 years old with and without a history of cancer who participated in annual cross-sectional National Health Interview Surveys from 1997 to 2014. Obesity was defined as body mass index ≥ 30 kg/m2 for non-Asians and body mass index ≥ 27.5 kg/m2 for Asians. Results Among 32,447 cancer survivors identified, the ...
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Greenlee, Shi, Sardo Molmenti, Rundle, Tsai Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.) Epidemiology Source Type: research

Barriers to Quality End-of-Life Care for Patients With Blood Cancers [Health Services and Outcomes]
Conclusion In this large national cohort of hematologic oncologists, standard EOL quality measures were highly acceptable. The top barrier to quality EOL care reported was unrealistic patient expectations, which may be best addressed with more timely and effective advance care discussions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Odejide, Cronin, Condron, Fletcher, Earle, Tulsky, Abel Tags: Quality of Care, End of Life, Outcomes Research, Quality of Care, Palliative Care Health Services and Outcomes Source Type: research

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer [Rapid Communication]
Conclusion Durvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1–positive patients with UBC, many of whom were heavily pretreated. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Massard, Gordon, Sharma, Rafii, Wainberg, Luke, Curiel, Colon-Otero, Hamid, Sanborn, ODonnell, Drakaki, Tan, Kurland, Rebelatto, Jin, Blake-Haskins, Gupta, Segal Tags: Phase I and Clinical Pharmacology, Translational Oncology, Rapid Communications, Rapid Communications, Other, Phase I and Clinical Pharmacology Source Type: research

Evaluating Quality Metrics for the Care of Patients With Blood Cancer Who Are Near Death [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Trevino, Martin, Prigerson Tags: Leukemia, Lymphoma, End of Life EDITORIALS Source Type: research

Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Drake, Bivalacqua, Hahn Tags: Translational Oncology, Immunology/Immunobiology EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to J. Nudelman [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Asdourian, Skolny, Brunelle, Seward, Salama, Taghian Tags: CORRESPONDENCE Source Type: research

Reply to A. Gomberawalla et al and J. Nudelman [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Ahn, Port Tags: CORRESPONDENCE Source Type: research

Do No Harm: Lymphedema Risk Reduction Behaviors [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Nudelman Tags: CORRESPONDENCE Source Type: research

LYMPHA: New Innovation, Not Old Practice [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gomberawalla, Feldman Tags: CORRESPONDENCE Source Type: research

Reply to F. Felix et al and M.F. Fay et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Happold, Gorlia, Chinot, Gilbert, Nabors, Wick, Pugh, Hegi, Cloughesy, Roth, Reardon, Perry, Mehta, Stupp, Weller Tags: CORRESPONDENCE Source Type: research

Valproate in Adjuvant Glioblastoma Treatment [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Fay, Head, Sminia, Dowson, Cosgrove, Rose, Martin Tags: CORRESPONDENCE Source Type: research

Valproic Acid May Be Tested in Patients With H3F3A-Mutated High-Grade Gliomas [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Felix, Fontenele Tags: CORRESPONDENCE Source Type: research

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline [ASCO SPECIAL ARTICLE]
Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) –positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. Recommendat...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Rugo, Rumble, Macrae, Barton, Connolly, Dickler, Fallowfield, Fowble, Ingle, Jahanzeb, Johnston, Korde, Khatcheressian, Mehta, Muss, Burstein Tags: Epidemiology, Chemotherapy, Combined Modality, Hormonal Therapy, ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study [Gynecologic Cancer]
Purpose The clinicopathologic significance of mismatch repair (MMR) defects in endometrioid endometrial cancer (EEC) has not been definitively established. We undertook tumor typing to classify MMR defects to determine if MMR status is prognostic or predictive. Methods Primary EECs from NRG/GOG0210 patients were assessed for microsatellite instability (MSI), MLH1 methylation, and MMR protein expression. Each tumor was assigned to one of four MMR classes: normal, epigenetic defect, probable mutation (MMR defect not attributable to MLH1 methylation), or MSI-low. The relationships between MMR classes and clinicopathologic va...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: McMeekin, Tritchler, Cohn, Mutch, Lankes, Geller, Powell, Backes, Landrum, Zaino, Broaddus, Ramirez, Gao, Ali, Darcy, Pearl, DiSilvestro, Lele, Goodfellow Tags: Epidemiology, Diagnosis & Staging Gynecologic Cancer Source Type: research

Characteristics of Patients Who Survived 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection? [Surgical Oncology]
Purpose Survival after metastatic cancer has improved at the cost of increased presentation with metastatic spinal disease. For patients with pathologic spinal fractures and/or spinal cord compression, surgical intervention may relieve pain and improve quality of life. Surgery is generally considered to be inappropriate if anticipated survival is
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Verlaan, Choi, Versteeg, Albert, Arts, Balabaud, Bunger, Buchowski, Chung, Coppes, Crockard, Depreitere, Fehlings, Harrop, Kawahara, Kim, Lee, Leung, Liu, Martin-Benlloch, Massicotte, Mazel, Meyer, Peul, Quraishi, Tokuhashi, Tomita, Ulbricht, Wang, Oner Tags: Prognostic Studies, Palliative Care, Surgical Oncology Source Type: research

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) [Gastrointestinal Cancer]
The objective of this study was to further validate ColDx using formalin-fixed, paraffin-embedded specimens collected as part of the Alliance phase III trial, C9581. Patients and Methods C9581 evaluated edrecolomab versus observation in patients with stage II CC and reported no survival benefit. Under an initial case-cohort sampling design, a randomly selected subcohort (RS) comprised 514 patients from 901 eligible patients with available tissue. Forty-nine additional patients with recurrence events were included in the analysis. Final analysis comprised 393 patients: 360 RS (58 events) and 33 non-RS events. Risk status w...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Niedzwiecki, Frankel, Venook, Ye, Friedman, Goldberg, Mayer, Colacchio, Mulligan, Davison, OBrien, Kerr, Johnston, Kennedy, Harkin, Schilsky, Bertagnolli, Warren, Innocenti Tags: Translational Oncology, Gastrointestinal, Gene Expression and Profiling Gastrointestinal Cancer Source Type: research

DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics [Gastrointestinal Cancer]
Conclusion dMMR rectal cancer had excellent prognosis and pathologic response with current multimodality therapy including an individualized surgical treatment plan. Identification of a dMMR rectal cancer should trigger germline testing, followed by lifelong surveillance for both colorectal and extracolorectal malignancies. We herein provide genotype-specific outcome benchmarks for comparison with novel interventions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: de Rosa, Rodriguez-Bigas, Chang, Veerapong, Borras, Krishnan, Bednarski, Messick, Skibber, Feig, Lynch, Vilar, You Tags: Surgery, Combined Modality, Translational Oncology, Surgical Oncology Gastrointestinal Cancer Source Type: research

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward [Pediatric Oncology]
Conclusion The EFS was uniformly poor for children with recurrent/refractory osteosarcoma in these single-arm phase II trials. We have now constructed baseline EFS outcomes that can be used as a comparison for future phase II trials for recurrent osteosarcoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Lagmay, Krailo, Dang, Kim, Hawkins, Beaty, Widemann, Zwerdling, Bomgaars, Langevin, Grier, Weigel, Blaney, Gorlick, Janeway Tags: Osteosarcoma Pediatric Oncology Source Type: research

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy [Pediatric Oncology]
Purpose Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with a broad spectrum of clinical manifestations and outcomes in children. The somatic BRAFV600E mutation occurs frequently, but clinical significance remains to be determined. Patients and Methods BRAFV600E mutation was investigated in a French LCH cohort. We analyzed associations between mutation status and clinical presentation, extent of disease, reactivation rate, response to therapy, and long-term permanent sequelae. Results Among 315 patients with successfully determined BRAF status, 173 (54.6%) carried a BRAFV600E mutation. Patients ...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Heritier, Emile, Barkaoui, Thomas, Fraitag, Boudjemaa, Renaud, Moreau, Peuchmaur, Chassagne-Clement, Dijoud, Rigau, Moshous, Lambilliotte, Mazingue, Kebaili, Miron, Jeziorski, Plat, Aladjidi, Ferster, Pacquement, Galambrun, Brugieres, Leverger, Mansuy, Pa Tags: Histiocytic Disorders, Oncogenes Pediatric Oncology Source Type: research

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials [Cancer Related Complications]
We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy. Results A total of 1...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Hershman, Till, Wright, Awad, Ramsey, Barlow, Minasian, Unger Tags: Outcomes Research Cancer Related Complications Source Type: research

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 [Urologic Oncology]
Purpose Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC. Patients and Methods Men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were randomly assigned at a two-to-one ratio to cabozantinib 60 mg once per day or prednisone 5 mg twice per day. The primary end point was overall survival (OS). Bone scan response (BSR) at week 12 as assessed by ...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Smith, De Bono, Sternberg, Le Moulec, Oudard, De Giorgi, Krainer, Bergman, Hoelzer, De Wit, Bogemann, Saad, Cruciani, Thiery-Vuillemin, Feyerabend, Miller, Houede, Hussain, Lam, Polikoff, Stenzl, Mainwaring, Ramies, Hessel, Weitzman, Fizazi Tags: Systemic Therapy Urologic Oncology Source Type: research

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736 [Hematologic Malignancy]
Conclusion Although 5-year PFS and OS were improved after early analysis in patients with limited-stage DLBCL receiving CHOP3RT versus CHOP8, extended survival data showed similar PFS and OS, with continuous treatment failure. The addition of rituximab (S0014) to combined-modality therapy did not mitigate the continued relapse risk, underscoring the value of prolonged clinical trial patient observation and possible unique biology of limited-stage DLBCL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Stephens, Li, LeBlanc, Puvvada, Persky, Friedberg, Smith Tags: Clinical Trials, Radiation, Chemotherapy, Combined Modality Hematologic Malignancy Source Type: research